← Leaderboards
William G. Powderly
Washington University
$79,446,872
Attributed
$79,446,872
Total exposure
11
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $10.5M · FY2019–25$20M$15M$10M$5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$79,446,872 · 11
By mechanism
UL1$68,740,960 · 1
U01$7,486,073 · 1
T32$1,534,489 · 1
R01$924,625 · 1
P01$691,205 · 1
M01$69,520 · 6
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- Kelle H Moley$25,167,882
- Douglas Lee Chalker$4,083,963
- Dineo Khabele$4,937,606
- Colin Pieter Derdeyn$10,282,174
- Paul M Allen$24,153,654
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHiv InfectionsAids TherapyProtease InhibitorHuman Therapy EvaluationUniversitiesClinical SciencesTranslational ResearchAntiaids AgentWashingtonResearch PersonnelCommunitiesInnovationInstitutionResourcesDigitalParticipantProgramsCommunity HealthComplexMissouriEnsureFaculty
Grant awards (38)
Washington University Institute of Clinical and Translational Sciences$9,335,360
UL1 · FY2025 · TR · contact PI
Washington University Institute of Clinical and Translational Sciences$10,136,690
UL1 · FY2024 · TR · contact PI
Washington University Institute of Clinical and Translational Sciences$10,178,414
UL1 · FY2023 · TR · contact PI
Washington University Institute of Clinical and Translational Sciences$233,250
UL1 · FY2023 · TR · contact PI
Washington University Institute of Clinical and Translational Sciences$53,969
UL1 · FY2023 · TR · contact PI
Washington University Institute of Clinical and Translational Sciences$10,161,090
UL1 · FY2022 · TR · contact PI
Washington University Institute of Clinical Translational Sciences$9,359,641
UL1 · FY2021 · TR · contact PI
WASHINGTON UNIVERSITY INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES$67,736
UL1 · FY2021 · TR · contact PI
Washington University Institute of Clinical Translational Sciences$9,359,641
UL1 · FY2020 · TR · contact PI
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES$339,611
UL1 · FY2020 · TR · contact PI
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES$155,917
UL1 · FY2020 · TR · contact PI
Washington University Institute of Clinical Translational Sciences$9,359,641
UL1 · FY2019 · TR · contact PI
Rosiglitazone &Exercise Training: Effects on HIV-Infected People$58,427
M01 · FY2004 · RR
WU 122: EVALUATE METABOLIC EFFECTS OF DISCONTINUATION OF ANTIRETROVIRAL THERAPY$5,917
M01 · FY2004 · RR
STUDY OF ONCE-WEEKLY ALENDRONATE IN HIV-INFECTED SUBJECTS$5,176
M01 · FY2004 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,877,686
U01 · FY2003 · AI
INFECTIOUS DISEASE/BASIC MICROBIAL PATHOGENIC MECHANISMS$506,968
T32 · FY2003 · AI
PATIENT RECRUITMENT &CLINICAL MANAGEMENT CORE$231,000
R01 · FY2003 · DK
ADULT AIDS CLINICAL TRIALS UNIT$1,935,539
U01 · FY2002 · AI
CORE--CLINICAL FACILITY$289,716
P01 · FY2002 · AI
PATIENT RECRUITMENT &CLINICAL MANAGEMENT CORE$231,000
R01 · FY2002 · DK
T20 with abacavir, amprenavir and efavirenz in HIV$0
M01 · FY2002 · RR
ACTG A5047:Pharmacokinetic interactions with protease inhibitors &lipid lowering$0
M01 · FY2002 · RR
ACTG 400: PHASE 2 TRIAL OF SALVAGE ANTIRETROVIRAL THERAPIES FOR HIV INFECTION$0
M01 · FY2002 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,786,066
U01 · FY2001 · AI
INFECTIOUS DISEASE/BASIC MICROBIAL PATHOGENIC MECHANISMS$527,997
T32 · FY2001 · AI
CORE--CLINICAL FACILITY$289,716
P01 · FY2001 · AI
PATIENT RECRUITMENT &CLINICAL MANAGEMENT CORE$231,000
R01 · FY2001 · DK
ACTG A5047:Pharmacokinetic interactions with protease inhibitors &lipid lowering$0
M01 · FY2001 · RR
T20 with abacavir, amprenavir and efavirenz in HIV$0
M01 · FY2001 · RR
ACTG 400: PHASE 2 TRIAL OF SALVAGE ANTIRETROVIRAL THERAPIES FOR HIV INFECTION$0
M01 · FY2001 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,886,782
U01 · FY2000 · AI
INFECTIOUS DISEASE/BASIC MICROBIAL PATHOGENIC MECHANISMS$499,524
T32 · FY2000 · AI
PATIENT RECRUITMENT &CLINICAL MANAGEMENT CORE$231,625
R01 · FY2000 · DK
CORE--CLINICAL FACILITY$111,773
P01 · FY2000 · AI
ACTG A5047:Pharmacokinetic interactions with protease inhibitors &lipid lowering$0
M01 · FY2000 · RR
T20 with abacavir, amprenavir and efavirenz in HIV$0
M01 · FY2000 · RR
ACTG 400: PHASE 2 TRIAL OF SALVAGE ANTIRETROVIRAL THERAPIES FOR HIV INFECTION$0
M01 · FY2000 · RR